Business

India’s Cardiac Medication Market Surges Over 50% in Five Years Amid Rising Heart Disease

That marks a compound annual growth rate of around 10.7%, according to a Pharmarack report analyzing data from 17 of the country's leading pharma companies.

• By Newsdesk
• New Delhi
• Jul 21, 2025

Business

India has seen a sharp rise in cardiac medication sales—jumping more than 50% between June 2021 and June 2025, increasing from ₹1,761 crore to ₹2,645 crore. That marks a compound annual growth rate of around 10.7%, according to a Pharmarack report analyzing data from 17 of the country's leading pharma companies.

This ballooning demand reflects several intertwined trends. First, updated clinical standards now consider blood pressure readings above 120 mmHg as elevated. This shift, along with wider availability of screening and diagnostic services, has brought many more patients into treatment pipelines. At the same time, India’s aging population—combined with growing burdens of diabetes, obesity, stress, and sedentary lifestyles—is pushing heart disease into younger age groups.

While cholesterol-lowering statins remain widely used, the market is also expanding rapidly for medications targeting heart failure, arrhythmia, angina, platelet aggregation, and blood thinning. In the heart failure segment alone, sales climbed 83% over five years and nearly 19% within the past year—totaling ₹1,304 crore.

Cardiovascular diseases now account for roughly 27% of all deaths in India, and non‑communicable diseases as a whole make up 63% of total mortality—a sobering reminder of the escalating public health challenge.

What emerges is a trend that is both hopeful and worrying: more people are recognizing and treating heart conditions, but the underlying surge in these illnesses points to deeper societal issues. The data underscores the need for two-pronged action: broadened access to diagnostics and treatment, and aggressive, community-based lifestyle interventions—targeting diet, exercise habits, pollution, and stress management.

(With inputs from The Economic Times)